Respiratory Inhaler Devices Market
  • Published Date: Aug-2021
  • |
  • 180 Pages
  • |
  • Report ID: MD0067

Respiratory Inhaler Devices Market

The Respiratory Inhaler Devices market is expected to grow from USD 36.27 billion in 2019 to USD 45.89 billion by 2025 at a CAGR of 4% from 2019 to 2025.

  • Report Description
  • Table of Content
  • Segmentation
  • Companies
  • News

Respiratory inhalator devices are medical devices are wont to assist a patient encountering respiration issues ensuing from metastasis disorders like pathology, asthma, COPD and respiratory disorder et al. On the premise of product kind, the market has been divided into dry powder inhalator (DPI), metered-dose inhalator (MDI) and the nebuliser. Nebuliser is more sub-segmented into a compressed gas nebulizer, ultrasonic nebulizer and mesh nebulizer. The global market is segregated on the basis of Disease Indication as Asthma, COPD, Pulmonary Arterial Hypertension, and Other Respiratory Disease. Based on Technology the market is segmented in Manually Operated Inhaler Devices and Digitally Operated Inhaler Devices. Based on Product the market is segmented in Dry Powder Inhaler, Metered Dose Inhaler, and Nebulizer.

The global market report provides geographical analysis covering regions, such as North America, Europe, Asia-Pacific, and the Rest of the World. The market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.

Competitive Rivalry

AstraZeneca, Beximco Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, Cipla Ltd., GlaxoSmithKline plc, Koninklijke Philips N.V., Merck & Co., Inc., OMRON Healthcare Europe B.V., PARI Medical Holding, Teva Pharmaceutical Industries Ltd, and others are among the major players in the market. The companies studied in terms of product strategy and various n several growths and expansion strategies to gain a competitive edge in the market. The major players not only follow value chain integration with business operations in multiple stages of the value chain.

The global Respiratory Inhaler Devices market has been segmented as below:

By Disease Indication

  • Asthma
  • COPD
  • Pulmonary Arterial Hypertension
  • Others Respiratory Disease

By Technology

  • Manually Operated Inhaler Devices
  • Digitally Operated Inhaler Devices

By Product

  • Dry Powder Inhaler
  • Metered Dose Inhaler
  • Nebulizer
    • Ultrasonic Nebulizer
    • Compressed Air Nebulizer
    • Mesh Nebulizer

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Respiratory Inhaler Devices Market, By Company

  • AstraZeneca
  • Beximco Pharmaceuticals Ltd.
  • Boehringer Ingelheim GmbH
  • Cipla Ltd.
  • GlaxoSmithKline plc
  • Koninklijke Philips N.V.
  • Merck & Co., Inc.
  • OMRON Healthcare Europe B.V.
  • PARI Medical Holding
  • Teva Pharmaceutical Industries Ltd

The report covers the below scope:

  • Global market sizes from 2019 to 2025, along with CAGR for 2020-2025
  • Market size comparison for 2020 vs 2025, with actual data for 2020, estimates for 2021 and forecast from 2021 to 2025
  • Global market trends, covering a comprehensive range of consumer trends & manufacturer trends
  • Value chain analysis covering participants from raw material suppliers to the downstream buyer in the market
  • Major market opportunities and challenges in forecast timeframe to be focused
  • Competitive landscape with analysis of competition pattern, portfolio comparisons, development trends, and strategic management
  • Comprehensive company profiles of the key industry players

The years considered for the study are as follows:

  • Base year - 2019
  • Estimated year - 2020
  • Projected year - 2021
  • Forecast period - 2021 to 2025

Report Scope:

The global market report scope includes a detailed study covering underlying factors influencing the industry trends. The report covers the analysis of regional and country-level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies. The report scope includes a detailed competitive outlook covering market shares and profiles key participants in the market share. Major industry players with significant revenue share include AstraZeneca, Beximco Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, Cipla Ltd., GlaxoSmithKline plc, Koninklijke Philips N.V., Merck & Co., Inc., OMRON Healthcare Europe B.V., PARI Medical Holding, Teva Pharmaceutical Industries Ltd, and others.

Why to Buy this Report:

  • Gain detailed insights on the Respiratory Inhaler Devices industry trends
  • Find a complete analysis of the market status
  • Identify the market opportunities and growth segments
  • Analyze competitive dynamics by evaluating business segments & product portfolios
  • Facilitate strategy planning and industry dynamics to enhance decision making

Target Audience:

The report targeted the existing players in the industry is as follows:

  • Market Manufacturers/Service Providers
  • Market Wholesale/Traders
  • Investment and Financial Institutions

Free and Paid Customization based on the requirement

Report Content

1. Introduction

  1.1 Key Insights

1.2 Report Overview 1.3 Markets Covered 1.4 Stakeholders 2. Research Methodology 2.1 Research Scope 2.2 Market Research Process 2.3 Research Data Analysis 2.4.1 Secondary Research 2.4.2 Primary Research 2.4.3 Models for Estimation 2.5 Market Size Estimation 2.5.1 Bottom-Up Approach - Segmental Market Analysis 2.5.2 Top-Down Approach - Parent Market Analysis 3. Executive Summary 4. Market Overview 4.1 Introduction 4.2.1 Drivers 4.2.2 Restraints 4.2.3 Opportunities 4.2.4 Challenges 4.2 Porter's Five Force Analysis 5. Respiratory Inhaler Devices Market, By Disease Indication 5.1 Introduction 5.2 Asthma 5.2.1 Market Overview 5.2.2 Market Size and Forecast 5.3 COPD 5.3.1 Market Overview 5.3.2 Market Size and Forecast 5.4 Pulmonary Arterial Hypertension 5.4.1 Market Overview 5.4.2 Market Size and Forecast 5.5 Others Respiratory Disease 5.5.1 Market Overview 5.5.2 Market Size and Forecast 6. Respiratory Inhaler Devices Market, By Technology 6.1 Introduction 6.2 Manually Operated Inhaler Devices 6.2.1 Market Overview 6.2.2 Market Size and Forecast 6.3 Digitally Operated Inhaler Devices 6.3.1 Market Overview 6.3.2 Market Size and Forecast 7. Respiratory Inhaler Devices Market, By Product 7.1 Introduction 7.2 Dry Powder Inhaler 7.2.1 Market Overview 7.2.2 Market Size and Forecast 7.3 Metered Dose Inhaler 7.3.1 Market Overview 7.3.2 Market Size and Forecast 7.4 Nebulizer 7.4.1 Market Overview 7.4.2 Market Size and Forecast 8. Respiratory Inhaler Devices Market, By Geography 8.1 Introduction 8.2 North America 8.2.1 North America Respiratory Inhaler Devices, By Disease Indication 8.2.2 North America Respiratory Inhaler Devices, By Technology 8.2.3 North America Respiratory Inhaler Devices, By Product 8.3 Europe 8.3.1 Europe Respiratory Inhaler Devices, By Disease Indication 8.3.2 Europe Respiratory Inhaler Devices, By Technology 8.3.3 Europe Respiratory Inhaler Devices, By Product 8.4 Asia-Pacific 8.4.1 Asia-Pacific Respiratory Inhaler Devices, By Disease Indication 8.4.2 Asia-Pacific Respiratory Inhaler Devices, By Technology 8.4.3 Asia-Pacific Respiratory Inhaler Devices, By Product 8.5 Rest of the World 8.5.1 Rest of the World Respiratory Inhaler Devices, By Disease Indication 8.5.2 Rest of the World Respiratory Inhaler Devices, By Technology 8.5.3 Rest of the World Respiratory Inhaler Devices, By Product 9. Competitive Insights 9.1 Key Insights 9.2 Company Market Share Analysis 9.3 Strategic Outlook 9.3.1 Mergers & Acquisitions 9.3.2 New Product Development 9.3.3 Portfolio/Production Capacity Expansions 9.3.4 Joint Ventures, Collaborations, Partnerships & Agreements 9.3.5 Others 10. Company Profiles 10.1 AstraZeneca 10.1.1 Company Overview 10.1.2 Product/Service Landscape 10.1.3 Financial Overview 10.1.4 Recent Developments 10.2 Beximco Pharmaceuticals Ltd. 10.2.1 Company Overview 10.2.2 Product/Service Landscape 10.2.3 Financial Overview 10.2.4 Recent Developments 10.3 Boehringer Ingelheim GmbH 10.3.1 Company Overview 10.3.2 Product/Service Landscape 10.3.3 Financial Overview 10.3.4 Recent Developments 10.4 Cipla Ltd. 10.4.1 Company Overview 10.4.2 Product/Service Landscape 10.4.3 Financial Overview 10.4.4 Recent Developments 10.5 GlaxoSmithKline plc 10.5.1 Company Overview 10.5.2 Product/Service Landscape 10.5.3 Financial Overview 10.5.4 Recent Developments 10.6 Koninklijke Philips N.V. 10.6.1 Company Overview 10.6.2 Product/Service Landscape 10.6.3 Financial Overview 10.6.4 Recent Developments 10.7 Merck & Co., Inc. 10.7.1 Company Overview 10.7.2 Product/Service Landscape 10.7.3 Financial Overview 10.7.4 Recent Developments 10.8 OMRON Healthcare Europe B.V. 10.8.1 Company Overview 10.8.2 Product/Service Landscape 10.8.3 Financial Overview 10.8.4 Recent Developments 10.9 PARI Medical Holding 10.9.1 Company Overview 10.9.2 Product/Service Landscape 10.9.3 Financial Overview 10.9.4 Recent Developments 10.10 Teva Pharmaceutical Industries Ltd 10.10.1 Company Overview 10.10.2 Product/Service Landscape 10.10.3 Financial Overview 10.10.4 Recent Developments

The global Respiratory Inhaler Devices market has been segmented as below:

By Disease Indication

  • Asthma
  • COPD
  • Pulmonary Arterial Hypertension
  • Others Respiratory Disease

By Technology

  • Manually Operated Inhaler Devices
  • Digitally Operated Inhaler Devices

By Product

  • Dry Powder Inhaler
  • Metered Dose Inhaler
  • Nebulizer
    • Ultrasonic Nebulizer
    • Compressed Air Nebulizer
    • Mesh Nebulizer

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Top 10 Companies in Respiratory Inhaler Devices Market, 

  • AstraZeneca
  • Beximco Pharmaceuticals Ltd.
  • Boehringer Ingelheim GmbH
  • Cipla Ltd.
  • GlaxoSmithKline plc
  • Koninklijke Philips N.V.
  • Merck & Co., Inc.
  • OMRON Healthcare Europe B.V.
  • PARI Medical Holding
  • Teva Pharmaceutical Industries Ltd

License Options

  • Single 1500 USD
  • Multiple 3000 USD